--- title: "Dermata Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286311064.md" datetime: "2026-05-13T20:17:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286311064.md) - [en](https://longbridge.com/en/news/286311064.md) - [zh-HK](https://longbridge.com/zh-HK/news/286311064.md) --- # Dermata Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.48. EBIT: As of FY2026 Q1, the actual value is USD -2.005 M. Dermata Therapeutics, Inc. operates as a single segment, focusing on the development, branding, marketing, and commercialization of direct-to-consumer skincare products. #### Operational Metrics - **Net Loss**: The net loss for the three months ended March 31, 2026, was - $1,847,706, an improvement from the - $2,303,587 loss reported for the same period in 2025. - **Loss from Operations**: The loss from operations was - $1,926,382 for the three months ended March 31, 2026, compared to - $2,339,803 for the three months ended March 31, 2025. - **Research and Development Expenses**: These expenses decreased by $0.9 million, from $1,281,141 for the three months ended March 31, 2025, to $383,724 for the three months ended March 31, 2026, primarily due to a $0.7 million reduction in clinical expenses from the XYNGARI™ STAR-1 acne study, $0.1 million less in chemistry, manufacturing, and controls (CMC) and non-clinical expenses, and $0.1 million less in personnel expenses, partially offset by Employee Retention Tax Credit refund proceeds. - **Clinical**: - $0 for the three months ended March 31, 2026, versus $726,321 in 2025. - **Chemistry, Manufacturing and Controls and Nonclinical**: $32,502 for the three months ended March 31, 2026, versus $125,290 in 2025. - **Personnel Related (R&D)**: $351,222 for the three months ended March 31, 2026, versus $429,530 in 2025. - **Selling, General and Administrative Expenses**: These expenses increased by approximately $0.5 million, from $1,058,662 for the three months ended March 31, 2025, to $1,542,658 for the three months ended March 31, 2026, mainly driven by $0.2 million in marketing expenses, $0.2 million in increased audit fees, and $0.1 million in increased legal fees. - **Compliance**: $1,011,796 for the three months ended March 31, 2026, versus $719,644 in 2025. - **Marketing**: $206,333 for the three months ended March 31, 2026, versus - $0 in 2025. - **Personnel Related (SG&A)**: $324,529 for the three months ended March 31, 2026, versus $339,018 in 2025. - **Interest Income**: Interest income increased to $78,676 for the first quarter of 2026, up from $36,216 for the first quarter of 2025. - **Stock-based Compensation Expense**: Total stock-based compensation expense was $43,278 for the three months ended March 31, 2026, compared to $37,189 for the same period in 2025. #### Cash Flow - **Net Cash Used in Operating Activities**: Cash used in operations was - $2,479,718 for the three months ended March 31, 2026, compared to - $1,934,066 for the same period in 2025. - **Net Cash Provided by Financing Activities**: Cash provided by financing activities was $1,903,022 for the three months ended March 31, 2026, compared to $8,491,764 for the same period in 2025. - **Cash and Cash Equivalents**: Cash and cash equivalents totaled $6,945,282 as of March 31, 2026, a decrease from $7,521,978 as of December 31, 2025. #### Unique Metrics - **Accumulated Deficit**: The accumulated deficit was - $75,081,602 as of March 31, 2026, compared to - $73,233,896 as of December 31, 2025. - **Inventory**: Inventory, consisting of raw materials for Tome skincare products, was $93,091 as of March 31, 2026, up from - $0 as of December 31, 2025. #### Future Outlook and Strategy Dermata Therapeutics, Inc. has strategically shifted its focus from prescription products to becoming a science-driven leader in direct-to-consumer (DTC) and business-to-business (B2B) dermatologic solutions, anticipating the launch of its first DTC products from the Tome skincare line in mid-2026. This repositioning aims to accelerate commercialization, reduce regulatory burden, and decrease development expenses, leveraging its _Spongilla lacustris_ Bioneedle technology. The company expects to incur net losses for at least the next twelve months, with increased selling, general, and administrative expenses related to marketing and branding for product launches, while research and development expenses are expected to decrease. #### Liquidity and Capital Requirements As of March 31, 2026, Dermata Therapeutics, Inc. had $6.9 million in cash and cash equivalents, which are expected to fund operations into the first quarter of 2027. The company acknowledges substantial doubt about its ability to continue as a going concern and plans to raise additional capital through equity or debt offerings, generate product revenue, or pursue licensing/collaboration transactions, noting there is no assurance of sufficient financing availability. ### Related Stocks - [DRMA.US](https://longbridge.com/en/quote/DRMA.US.md) ## Related News & Research - [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Acenta Group delays Q1 interim report release to May 29, 2026](https://longbridge.com/en/news/287031560.md) - [OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | OSTX Stock News](https://longbridge.com/en/news/286607728.md)